Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade) [Seeking Alpha]
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Seeking Alpha
The company focuses on developing gene therapies for rare diseases, targeting a market that is expected to triple in value by the end of the decade. Rocket's pipeline includes promising therapies for severe leukocyte adhesion deficiency-I, Danon Disease, and Fanconi Anemia, among others. An updated analysis around Rocket Pharmaceuticals follows in the paragraphs below. Looking for more investing ideas like this one? Get them exclusively at The Biotech Forum. Learn More » Shares of gene therapy concern Rocket Pharmaceuticals, Inc. ( NASDAQ: RCKT have risen by 20% since we last looked at it in May of last year, as the company is poised for two potential FDA approvals. Furthermore, its one potential blockbuster rare disease gene therapy, RP-A501 for the treatment of Danon Disease, began enrolling patients in 1H23 after very encouraging Phase 1 results. With its programs reversing disease and enough cash to get into 2026 – not counting revenue from any approved therapies – Rock
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $53.00 price target on the stock.MarketBeat
- EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch [Seeking Alpha]Seeking Alpha
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $39.00 price target on the stock.MarketBeat
RCKT
Earnings
- 2/26/24 - Beat
RCKT
Sec Filings
- 4/24/24 - Form 4
- 4/22/24 - Form 144
- 4/17/24 - Form PRE
- RCKT's page on the SEC website